Regression of posterior uveal melanomas following cobalt-60 plaque radiotherapy
A method has been devised for evaluating the rate and extent of regression of the first 100 consecutive patients with a posterior uveal melanoma that had been managed by Cobalt-60 plaque radiotherapy at Wills Eye Hospital. It was found that the average posterior uveal melanoma in the series did not regress rapidly to a flat, depigmented scar but shrank slowly and persisted as a residual mass approximately 50% of the thickness of the original tumor at 54 months following Cobalt-60 plaque radiotherapy. The authors also found that the rate and extent of regression of the tumors in patients who subsequently developed metastatic melanoma were not appreciably different from the rate and extent of regression of the tumors in patients who remained well systemically. These observations indicate that the rate and extent of regression of posterior uveal melanomas following Cobalt-60 plaque radiotherapy are poor indicators of the prognosis of the affected patients for subsequent development of clinical metastatic disease.
- Research Organization:
- Thomas Jefferson Univ., Philadelphia, PA
- OSTI ID:
- 5654145
- Journal Information:
- Ophthalmology (Rochester, Minn.); (United States), Journal Name: Ophthalmology (Rochester, Minn.); (United States) Vol. 91:12; ISSN OPHTD
- Country of Publication:
- United States
- Language:
- English
Similar Records
Cobalt plaque therapy of posterior uveal melanomas
Malignant melanoma of the eye: treatment of posterior uveal lesions by Co-60 plaque radiotherapy versus enucleation
Related Subjects
62 RADIOLOGY AND NUCLEAR MEDICINE
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
BODY AREAS
COBALT 60
COBALT ISOTOPES
COMPARATIVE EVALUATIONS
DISEASES
EYES
FACE
HEAD
INTERMEDIATE MASS NUCLEI
INTERNAL CONVERSION RADIOISOTOPES
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
MEDICINE
MELANOMAS
METASTASES
MINUTES LIVING RADIOISOTOPES
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-ODD NUCLEI
ORGANS
PATIENTS
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
SENSE ORGANS
SIDE EFFECTS
THERAPY
UVEA
YEARS LIVING RADIOISOTOPES